No annual revenue total was found in LeonaBio, Inc.'s SEC filings.
LeonaBio, Inc. (LONA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $51.1 million in cash and investments and $577,000 in total debt.
Revenue
—
Net income (TTM)
$-141.46M
-136.3% vs year-ago TTM
Operating cash flow (TTM)
$-61.93M
+12.4% vs year-ago TTM
Free cash flow
$-97.20M
+3.8% vs prior year
EPS (TTM)
$-10.96
-342.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.34M
+139.1% vs prior year
Net cash
$50.49M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LONA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1620463
- Former names
- Athira Pharma, Inc. (until Jan 8, 2026); M3 Biotechnology, Inc. (until Jan 23, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M |
| Net income | -$105.6M | -$96.9M | -$117.7M | -$95.6M | -$54.9M |
| Diluted EPS | -$24.70 | -$25.19 | -$3.09 | -$2.53 | — |
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M |
| Free cash flow | — | -$97.2M | -$101.1M | -$73.6M | -$44.7M |
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M |
| Stockholders' equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M |
| Cash and investments | $88.3M | $51.3M | $147.4M | $245.2M | $319.7M |
| Total debt | $803,000 | $1.2M | $1.6M | $1.9M | $1.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Other events
|
Aug 26, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
| ARS | Annual report to shareholders | May 11, 2026 | Dec 31, 2025 |
All 469 LeonaBio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.